The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials

Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, White, Paul Charles ORCID: https://orcid.org/0000-0002-6562-4696, Levis, Mark J., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Russell, Nigel H. and Burnett, Alan Kenneth 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21) , p. 194.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information:	53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis Location: San Diego, CA Date: DEC 10-13, 2011
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	06 Jan 2024 03:57
URI:	https://orca.cardiff.ac.uk/id/eprint/49787

Actions (repository staff only)

Edit Item